Molika Ashford

Investigators shared results of a study this week in which ctDNA residual disease testing gave advance notice of late recurrences in surgically resected HR+ HER2- patients.

Researchers reported prospective randomized trial data showing non-inferiority of adjuvant treatment guided by minimal residual disease testing.

The lead investigators have also spun out a company, Isabl, aiming to make the approach available to the broader community.

Stakeholders are working to harmonize strategies for overcoming the challenges faced by new blood-based multi-cancer early detection assays.

At the AACR annual meeting, both companies shared new data on their technologies' performance in detecting early and late-stage cancers.

The company published a pilot study showing that it's five-miRNA signature could predict which lung cancer patients survived longer on immunotherapy treatment.

The company aims to release an initial tissue-based prognostic this year, with a less-invasive sponge-sampling version for screening high-risk individuals to follow in 2023.

Illumina alleges that Guardant's founders misappropriated Illumina's confidential information and filed patent applications for their liquid biopsy startup based on Illumina's intellectual property.

Based on the results of their new study, City of Hope researchers advised doctors against overreliance on Natera's Signatera assays for recurrence monitoring.

As its research business increasingly tilts toward oncology, the firm has cemented plans for its first clinical test launch this year.